Abivax (NASDAQ:ABVX) Shares Gap Up – Here’s Why

Abivax SA Sponsored ADR (NASDAQ:ABVX) shares gapped up before the market opened on Thursday . The stock had previously closed at $112.31, but opened at $120.24. Abivax shares last traded at $115.1680, with a volume of 1,415,214 shares trading hands.

Analysts Set New Price Targets

ABVX has been the topic of several research analyst reports. Wedbush started coverage on shares of Abivax in a report on Tuesday, February 24th. They set an “outperform” rating and a $110.00 price target on the stock. Truist Financial set a $140.00 price objective on Abivax in a research report on Monday, November 24th. BTIG Research restated a “buy” rating and issued a $150.00 target price on shares of Abivax in a research note on Wednesday, February 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Abivax in a research report on Wednesday, January 21st. Finally, Oppenheimer set a $131.00 price target on Abivax in a research note on Thursday, January 8th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Abivax has a consensus rating of “Moderate Buy” and a consensus price target of $134.75.

Abivax Stock Performance

The company has a debt-to-equity ratio of 0.03, a quick ratio of 7.86 and a current ratio of 7.86. The company has a market cap of $9.25 billion, a P/E ratio of -27.99 and a beta of 1.00. The firm has a 50 day moving average price of $119.71 and a 200-day moving average price of $108.36.

Abivax (NASDAQ:ABVX) last issued its quarterly earnings data on Monday, December 15th. The company reported ($2.46) earnings per share for the quarter. The company had revenue of ($4.92) million during the quarter. On average, research analysts predict that Abivax SA Sponsored ADR will post -2.83 EPS for the current year.

Institutional Trading of Abivax

Several large investors have recently modified their holdings of ABVX. EverSource Wealth Advisors LLC grew its stake in Abivax by 4,612.5% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 377 shares of the company’s stock valued at $32,000 after buying an additional 369 shares during the last quarter. First Horizon Corp bought a new stake in Abivax during the third quarter valued at about $36,000. Bank of America Corp DE boosted its holdings in Abivax by 56.1% during the fourth quarter. Bank of America Corp DE now owns 5,536 shares of the company’s stock valued at $41,000 after acquiring an additional 1,990 shares during the period. Hantz Financial Services Inc. acquired a new stake in shares of Abivax in the third quarter valued at about $52,000. Finally, Caitong International Asset Management Co. Ltd increased its stake in shares of Abivax by 661.5% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 396 shares of the company’s stock worth $53,000 after purchasing an additional 344 shares during the period. 47.91% of the stock is owned by institutional investors.

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.